FDA Approval of Cardiac Valve Devices Implanted in a National Cohort of Pediatric Patients, 2016-2022.
作者信息
Wunnava Susmitha, Miller Timothy A, Nathan Meena, Bourgeois Florence T
机构信息
Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts.
Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts.
出版信息
JAMA Pediatr. 2025 May 1;179(5):570-573. doi: 10.1001/jamapediatrics.2025.0131.
Abstract
摘要
相似文献
1
FDA Approval of Cardiac Valve Devices Implanted in a National Cohort of Pediatric Patients, 2016-2022.2016 - 2022年美国儿科患者全国队列中心脏瓣膜装置的FDA批准情况
JAMA Pediatr. 2025 May 1;179(5):570-573. doi: 10.1001/jamapediatrics.2025.0131.
2
A new paradigm for obtaining marketing approval for pediatric-sized prosthetic heart valves.为儿科尺寸的人工心脏瓣膜获得营销批准的新模式。
J Thorac Cardiovasc Surg. 2013 Oct;146(4):879-86. doi: 10.1016/j.jtcvs.2013.04.016. Epub 2013 Jun 21.
3
The FDA Review Process for Cardiac Medical Devices in Children: A Review for the Clinician.美国食品药品监督管理局对儿童心脏医疗器械的审评流程：给临床医生的一份综述
Prog Pediatr Cardiol. 2012 May 1;33(2):105-109. doi: 10.1016/j.ppedcard.2012.02.002. Epub 2012 Mar 27.
4
Quantification of US Food and Drug Administration Premarket Approval Statements for High-Risk Medical Devices With Pediatric Age Indications.高风险医疗器械有儿科适应证的美国食品和药物管理局上市前批准声明的定量评估。
JAMA Netw Open. 2021 Jun 1;4(6):e2112562. doi: 10.1001/jamanetworkopen.2021.12562.
5
FDA Regulation and Approval of Medical Devices: 1976-2020.FDA 对医疗器械的监管与审批：1976-2020 年。
JAMA. 2021 Aug 3;326(5):420-432. doi: 10.1001/jama.2021.11171.
6
Postmarketing trials and pediatric device approvals.上市后试验与儿科医疗器械批准
Pediatrics. 2014 May;133(5):e1197-202. doi: 10.1542/peds.2013-3348. Epub 2014 Apr 14.
7
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.英格兰对有资格获得美国食品和药物管理局加速批准的癌症药物的覆盖范围评估。
JAMA Intern Med. 2021 Apr 1;181(4):490-498. doi: 10.1001/jamainternmed.2020.8441.
8
Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.2010 年和 2011 年 FDA 上市前批准的高风险治疗性医疗器械全产品生命周期临床试验特点。
JAMA. 2015 Aug 11;314(6):604-12. doi: 10.1001/jama.2015.8761.
9
Median approval times for class III medical devices have been well above statutory deadlines set for FDA and CMS.III 类医疗器械的平均批准时间远高于 FDA 和 CMS 设定的法定截止日期。
Health Aff (Millwood). 2012 Oct;31(10):2304-13. doi: 10.1377/hlthaff.2010.1198.
10
US FDA Advisory Panel Members' Assessment of Premarket Approval Process and Suggestions for Improvement.美国 FDA 顾问小组对上市前审批程序的评估及改进建议。
JAMA Netw Open. 2024 Oct 1;7(10):e2436066. doi: 10.1001/jamanetworkopen.2024.36066.
本文引用的文献
1
The Society of Thoracic Surgeons Congenital Heart Surgery Database: 2023 Update on Outcomes and Research.美国胸外科协会先天性心脏病外科学会数据库：2023 年关于结果和研究的更新。
Ann Thorac Surg. 2024 May;117(5):904-914. doi: 10.1016/j.athoracsur.2024.03.018. Epub 2024 Mar 24.
2
US Food and Drug Administration Approval of High-risk Cardiovascular Devices for Use in Children and Adolescents, 1977-2021.美国食品和药物管理局批准高风险心血管设备用于儿童和青少年，1977-2021 年。
JAMA. 2022 Aug 9;328(6):580-582. doi: 10.1001/jama.2022.10041.
3
Pediatric Medical Device Development and Regulation: Current State, Barriers, and Opportunities.儿科医疗器械的开发与监管：现状、障碍与机遇。
Pediatrics. 2022 May 1;149(5). doi: 10.1542/peds.2021-053390.
4
Off-label Medication Prescribing Patterns in Pediatrics: An Update.儿科非适应证用药处方模式：最新进展
Hosp Pediatr. 2019 Mar;9(3):186-193. doi: 10.1542/hpeds.2018-0168. Epub 2019 Feb 11.
5
Pediatric interventional cardiology in the United States is dependent on the off-label use of medical devices.美国的儿科介入心脏病学依赖于医疗器械的非标签使用。
Congenit Heart Dis. 2010 Jan-Feb;5(1):2-7. doi: 10.1111/j.1747-0803.2009.00364.x.
Zotero 插件